NEW YORK (GenomeWeb News) – Health Discovery Corp. announced yesterday that it had signed two diagnostics deals with Abbott and clinical lab company Quest Diagnostics.
Under the first alliance, Abbott acquired co-exclusive clinical lab rights and exclusive in vitro diagnostics rights to commercialize HDC's tissue-based and urine-based prostate cancer tests. The firm did not disclose any additional terms of the agreement.
Under the second deal, HDC licensed biomarkers to Quest for development of a non-invasive, urine-based prostate cancer test. Savannah, Ga.-based HDC will receive payments, royalties, and additional undisclosed financial considerations as part of the agreement.